Latest News & Features
Genetics
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies. 4 September 2014
Americas
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative. 4 September 2014
Big Pharma
English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva. 3 September 2014
Big Pharma
Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner. 3 September 2014
Europe
WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London. 2 September 2014
Americas
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29). 1 September 2014
Americas
The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday. 29 August 2014
Big Pharma
Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease. 28 August 2014
Americas
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid. 22 August 2014
Americas
The molecular diagnostic testing company GeneDx has petitioned the US Patent and Trademark Office to invalidate 11 patents asserted by Myriad in a lawsuit filed against GeneDx in October 2013. 21 August 2014